Holen Sie sich die Stockscreener-App
18.41
2.02%
-0.3782
Schlusskurs vom Vortag:
$18.79
Offen:
$18.94
24-Stunden-Volumen:
557.56K
Relative Volume:
0.73
Marktkapitalisierung:
$896.73M
Einnahmen:
$96.52M
Nettoeinkommen (Verlust:
$-164.64M
KGV:
-5.3181
EPS:
-3.4621
Netto-Cashflow:
$-144.11M
1W Leistung:
-10.02%
1M Leistung:
-8.41%
6M Leistung:
-2.02%
1J Leistung:
+68.90%
1-Tages-Spanne:
$17.94
$19.09
1-Wochen-Bereich:
$17.94
$21.05
52-Wochen-Spanne:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
18.42 | 914.74M | 96.52M | -164.64M | -144.11M | -3.4621 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.57 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.71 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.76 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.67 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Bladder cancer survey: 80% of patients live with fear it will return - Stock Titan
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support - GlobeNewswire Inc.
Jobs Data: Is UroGen Pharma Ltd stock showing strong momentumMarket Volume Report & Consistent Profit Trading Strategies - baoquankhu1.vn
UroGen Pharma Hits Day High with Strong 7.12% Intraday Surge - Markets Mojo
How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
UroGen closes up 43% ahead of FDA decision on bladder cancer candidate - MSN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
UroGen Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN - MarketBeat
Assessing UroGen Pharma (URGN) Valuation After Recent Share Price Volatility - simplywall.st
Q1 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push - Yahoo Finance
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile - simplywall.st
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation - Investing.com Australia
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating - TipRanks
NMIBC Market: Strong Pharma Growth Forecast Through 2034 - openPR.com
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales - Investing.com Australia
UroGen Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript - Insider Monkey
UroGen refinances debt with $250M facility at 8.25% rate - Investing.com India
UroGen reports $15.8M in ZUSDURI sales, refinances debt By Investing.com - Investing.com Canada
UroGen Pharma Strengthens Balance Sheet, Reports FY25 Results And ZUSDURI Launch Progress - Nasdaq
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives - simplywall.st
Urogen Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026 - Meyka
UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Stron - GuruFocus
Akin, an Elite Global Law Firm - Akin
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5%Should You Sell? - MarketBeat
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts - Investing.com Nigeria
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Urogen Pharma Q4 Earnings Call Highlights - MarketBeat
URGN: Analyst Maintains Buy Rating with $33 Target | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen (URGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
UroGen Pharma Amends Loan Agreement With Pharmakon Advisors - marketscreener.com
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
UroGen Pharma Q4 Net Loss Narrows, Revenue Rises - marketscreener.com
UroGen reports $15.8M in ZUSDURI sales, refinances debt - Investing.com India
Earnings Flash (URGN) UroGen Pharma Posts Q4 Net Loss $0.54 a Share, vs. FactSet Est of $0.50 Loss - marketscreener.com
UroGen Pharma (URGN) Secures Amended $250M Loan Agreement - GuruFocus
UroGen Pharma Secures New $250 Million Term Loan - TipRanks
UroGen's (URGN) Revenue Misses Estimates, Eyes Growth with ZUSDU - GuruFocus
UroGen Pharma (URGN) Projects Modest Growth in 2026 Jelmyto Sales - GuruFocus
UROGEN PHARMA ($URGN) Releases Q4 2025 Earnings - Quiver Quantitative
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):